Literature DB >> 16701094

Double mapping with subareolar blue dye and peritumoral green dye injections decreases the false-negative rate of dye-only sentinel node biopsy for early breast cancer: 2-site injection is more accurate than 1-site injection.

Keisei Anan1, Shoshu Mitsuyama, Hirotaka Kuga, Michiyo Saimura, Yoshitaka Tanabe, Nobuhiro Suehara, Hiroaki Matsunaga, Kazuyoshi Nishihara, Yuji Abe, Toshimitsu Iwashita, Takaaki Ihara, Keiyoshi Tamae, Minoru Ono, Satoshi Toyoshima.   

Abstract

BACKGROUND: The optimum sentinel node biopsy (SNB) mapping method for breast cancer remains to be determined. No matter which mapping agents are used, 2-site injection may be superior to 1-site injection in limiting the false-negative rate.
METHODS: We examined whether a double-mapping method with subareolar injection of blue dye and peritumoral injection of green dye would decrease the false-negative rate of dye-only SNB in 145 patients with early breast cancer.
RESULTS: The identification rate for blue-dyed and/or green-dyed (including mixed color-dyed) lymph nodes was 96.6% (140/145). Sensitivity and specificity were 95.1% (39/41) and 100% (99 of 99), respectively. Accuracy was 98.6% (138/140) with a false-negative rate of 4.9% (2/41). There were 4 patients in whom nodes of each color were found, but nodes of only 1 color were shown to be positive. The primary tumors of these 4 patients and of the 2 patients with false-negative results were located in the upper-outer quadrant of the breast. When only blue-dyed or green-dyed nodes (including mixed color-dyed nodes) were counted, the false-negative rates were 10.3% (4/39) for the subareolar mapping technique and 10.0% (4/40) for the peritumoral mapping technique.
CONCLUSIONS: The double-mapping method based on subareolar and peritumoral injections decreases the false-negative rate of dye-only SNB for early breast cancer. Variations in lymphatic channels may exist in the lateral half of the breast and thus may influence identification of positive sentinel nodes. This finding should be taken into account in cases of multicentric breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16701094     DOI: 10.1016/j.surg.2005.11.007

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

Review 1.  Current status of sentinel lymph-node biopsy in patients with breast cancer.

Authors:  Gang Cheng; Stephanie Kurita; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-11       Impact factor: 9.236

2.  Breast Cancer Sentinel Node Detection: An Alternative Solution for Centers Lacking Nuclear Technology.

Authors:  Mahmoud A Alhussini; Ahmed T Awad; Mohamed H Ashour; Ahmed Abdelateef; Haytham Fayed
Journal:  Breast Care (Basel)       Date:  2016-08-15       Impact factor: 2.860

3.  The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.

Authors:  Francesco Giammarile; Naomi Alazraki; John N Aarsvold; Riccardo A Audisio; Edwin Glass; Sandra F Grant; Jolanta Kunikowska; Marjut Leidenius; Valeria M Moncayo; Roger F Uren; Wim J G Oyen; Renato A Valdés Olmos; Sergi Vidal Sicart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-02       Impact factor: 9.236

4.  The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis.

Authors:  Sarah Pesek; Taka Ashikaga; Lars Erik Krag; David Krag
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

Review 5.  Nodal status assessment in breast cancer: strategies of clinical grounds and quality of life implications.

Authors:  Paolo Orsaria; Dimitrios Varvaras; Gianluca Vanni; Giampiero Pagnani; Jacopo Scaggiante; Federico Frusone; Alessandra Vittoria Granai; Giuseppe Petrella; Oreste Claudio Buonomo
Journal:  Int J Breast Cancer       Date:  2014-02-11

6.  An Ultralow-Dose 1-Day Protocol With Activities Lower Than 20 MBq for the Detection of Sentinel Lymph Nodes in Breast Cancer-Experiences After 150 Cases.

Authors:  Hans-Christian Kolberg; Shabnam Afsah; Thorsten Kuehn; Ute Winzer; Leyla Akpolat-Basci; Miltiades Stephanou; Sarah Wetzig; Oliver Hoffmann; Cornelia Liedtke
Journal:  Technol Cancer Res Treat       Date:  2017-09-06

7.  Comparison of a 1-day and a 2-day protocol for lymphatic mapping and sentinel lymph node biopsy in patients with nonpalpable breast cancer.

Authors:  S van Esser; M Hobbelink; J W Van Isselt; W P Th M Mali; I H M Borel Rinkes; R van Hillegersberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-25       Impact factor: 9.236

8.  Risk of node metastasis of sentinel lymph nodes detected in level II/III of the axilla by single-photon emission computed tomography/computed tomography.

Authors:  Hiroaki Shima; Goro Kutomi; Fukino Satomi; Hideki Maeda; Tomoko Takamaru; Hidekazu Kameshima; Tosei Omura; Mitsuru Mori; Masamitsu Hatakenaka; Tadashi Hasegawa; Koichi Hirata
Journal:  Exp Ther Med       Date:  2014-09-15       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.